Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Dexamethasone

Dexamethasone acetate

BB 1101

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Mezigdomide

Carfilzomib

BMS Study Connect Contact Center www.BMSStudyConnect.com

Omar Alkharabsheh, Site 0046

Amitabha Mazumder, Site 0005

Ashraf Aziz, Site 0190

Lasika Seneviratne, Site 0187

Site 0279

Leon Bernal-Mizrachi, Site 0291

Bobby Chawla, Site 0203

Site 0289

Monique Hartley-Brown, Site 0204

iuliana Shapira, Site 0222

Nishi Shah, Site 0199

Yvonne Efebera, Site 0172

Carrie Yuen, Site 0044

Rex Garland, Site 0195

Francis Senecal, Site 0006

Salah ud din Safi, Site 0243

Paola Ochoa, Site 0008

Dorotea Fantl, Site 0079

GUSTAVO BRAIDOT, Site 0182

Site 0319

Site 0150

Gustavo Jarchum, Site 0151

Phoebe Ho, Site 0077

Cecily Forsyth, Site 0160

Jock Simpson, Site 0263

Christopher Ward, Site 0078

Georgia Mccaughan, Site 0026

Cindy Lee, Site 0024

Nora Lee, Site 0131

Henry Prince, Site 0224

Jay Hocking, Site 0127

Hang Quach, Site 0025

Site 0266

Irene Strassl, Site 0020

Maria-Theresa Krauth, Site 0017

EDVAN CRUSOE, Site 0121

Marcelo Capra, Site 0076

Jayr Schmidt Filho, Site 0085

Angelo Maiolino, Site 0075

Vania Hungria, Site 0073

Site 0304

Site 0305

Site 0309

Darrell White, Site 0183

Martha Louzada, Site 0275

Donna Reece, Site 0184

Site 0318

Zhongxia Huang, Site 0057

wen gao, Site 0061

Junling Zhuang, Site 0056

Site 0123

Zhongjun Xia, Site 0138

Site 0315

Site 0051

Chunyan Sun, Site 0066

Site 0054

Site 0103

Jing Liu, Site 0071

Xiaoping Zhang, Site 0180

Hongming Huang, Site 0111

Chengcheng Fu, Site 0104

xin zhou, Site 0069

qingming wang, Site 0095

sujun gao, Site 0052

Xiaojing Yan, Site 0096

wei yang, Site 0176

YingMin Liang, Site 0060

Ming Hou, Site 0072

Site 0118

Site 0317

Yafei Wang, Site 0091

Site 0058

Zhen Cai, Site 0050

Site 0115

Site 0059

Kenny Galvez, Site 0153

Carmen Rosales, Site 0156

Site 0154

Henry Idrobo, Site 0155

Maja Vase, Site 0032

Trung Hieu Do, Site 0065

Charlotte Hansen, Site 0129

Site 0125

Natalie Schub, Site 0029

Site 0007

Marc-Steffen Raab, Site 0015

Site 0102

Maximilian Merz, Site 0030

Site 0133

Site 0124

Site 0014

Argiris Symeonidis, Site 0136

MELETIOS DIMOPOULOS, Site 0135

Site 0134

Bristol-Myers Squibb

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

This is a two-stage inferentially seamless design.

This is an open-label study; however, any review of aggregate study data by the Sponsor will be performed in a blinded manner.

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

VGPRR will be calculated as the percentage of participants who achieve best response of VGPR or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.

CRR will be calculated as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma.

The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.

The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

Anti-Infective Agents

Antibodies

Prednisone

Immunomodulating Agents

Immunoglobulins

Ixazomib

Proteasome Inhibitors

HIV Protease Inhibitors

Protease Inhibitors

Enzyme Inhibitors

Dose level -2: Mezigdomide: 0.3 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 2.3 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level -1: Mezigdomide: 0.6 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 2.3 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level 0 (Starting dose): Mezigdomide: 0.6 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 3.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level +1: Mezigdomide: 1.0 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 3.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level +2: Mezigdomide: 1.0 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 4.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22

Mezigdomide: RP2D daily on days 1-21 of a 28-day schedule Ixazomib: RP2D PO weekly on days 1, 8 and 15 of a 28-day schedule Dexamethasone: RP2D on days 1, 8, 15 and 22

Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.

Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.

Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.

Linda J Elias, RN

Kathleen A Dorritie, MD

Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases. While still considered an incurable disease, new treatments have improved outcomes dramatically over the last two decades. Around the turn of the millennium, classical cytotoxic chemotherapy and radiation were the only available treatment modalities and median OS was estimated at 2-3 years. Currently, there are now 17 FDA-approved anti-myeloma agents and median OS is approaching 10 years. More recently, next generation cellular and immune therapies are demonstrating unprecedented efficacy in highly refractory patients with otherwise a very short life expectancy. In this study, the starting dose of ixazomib will be reduced to 3mg, as this is the first FDA-recommended dose recommendation (from 4mg). The starting dose of mezigdomide will be 0.6mg. Frequent toxicity and AE monitoring as outlined in this trial (weekly in C1, every 2 weeks in C2-C4) asserts maximization of patient safety. Dexamethasone (DEX) will be dosed at 40mg weekly in patients \< 75 years old and 20mg for patients \> 76 years old. Additionally, the staring dose of DEX may be reduced to 20mg in any patient, per study provider discretion, based on several factors such frailty, prior adverse side effects or existing comorbidities.

Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD). It is an oral small-molecule compound that potentiates the cereblon-mediated ubiquitination of key cellular transcription factors (Ikaros and Aiolos), which ultimately results in multiple myeloma cell death and other immunomodulatory activity. Mezigdomide has demonstrated acceptable safety in two phase I clinical trials in combination with DEX as a "doublet," and as a "triplet" in combination with bortezomib and DEX. Early estimates of efficacy are high compared to historical date: 55% ORR in combination with DEX in a highly pre-treated and refractory patient population, and 75% in combination with bortezomib. By comparison, the most recent oral therapy approved by the FDA for RRMM was Selinexor, which demonstrated a 25% ORR in patients who received a median of 7 prior lines of therapy and 100% of whom were refractory to a PI, IMID and DARA. This comparison serves as very exploratory estimate as no conclusions can be drawn from cross-trial comparisons, especially with very small patient populations. While important efficacy measures such overall survival, progression-free survival and duration of response are maturing, these estimates suggest mezigdomide could be an efficacious, oral treatment option for patients with RRMM.

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dose-limiting toxicity (DLT) per adverse events as defined using National Cancer Institute (NCI) CTCAE v5.0. Hematologic DLTs: Grade 4 neutropenia \< 500/μL for more than 5 days, Grade 3 neutropenia with fever \> 38.3°C (one time) or fever \> 38.0°C sustained for one hour, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding; Non-Hematologic DLTs: Grade 3 diarrhea lasting \>3 days (not recovering to \< grade 2) despite supportive care, Grade 3 nausea or vomiting \>3 days (not recovering to \< grade 2) days despite supportive care, Grade 3 fatigue lasting \>7 days (not recovering to \< grade 2) days despite supportive care, Grade 4 diarrhea, Grade 4 nausea or vomiting, Allergic reaction or hypersensitivity if unable to be corrected to \<grade 1 within 48 hours, Any other non-hematologic grade \>3 toxicity for which there is not a clear alternative explanation; General: dose modification or delay of mezigdomide or ixazomib during cycle 1 due to treatment related toxicity.

Preliminary efficacy of mezigdomide when given in combination with ixazomib and dexamethasone as estimated by ORR, as defined by the International Myeloma Working Group (IMWG) response criteria. This will be expressed as the proportion of patients who achieve complete response (CR) or partial response (PR). CR is defined as negative serum and urine M-protein immunofixation (IF), along with the presence of \< 5% plasma cells (PCs) in bone marrow (BM) biopsy. PR is defined as ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours.

Incidence and severity of adverse events AEs, as defined by the NCI-Common Terminology Criteria for Adverse Events v5.0, tabulated by type, grade and relatedness to treatment for each dose level achieved in the study and overall.

Depth of Response will be measured as the proportion of participants in each category, given IMWG Uniform Response Criteria at each dose level and overall.

The time from the date of the earliest documented response (PR, VGPR, CR or sCR) to the earliest date of disease progression or death, whichever occurred first. Disease progression will be determined by the investigator per IMWG Uniform Response Criteria.

The time from the date of first treatment to the earliest date of disease progression or death, whichever occurred first. Disease progression will be determined by the investigator per IMWG Uniform Response Criteria.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)	NCT05552976	Relapsed or Ref...	Mezigdomide Carfilzomib Dexamethasone	18 Years -	Bristol-Myers Squibb
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma	NCT06050512	Relapsed and Re...	Mezigdomide Ixazomib Dexamethasone	18 Years -	University of Pittsburgh
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	NCT05519085	Relapsed or Ref...	mezigdomide Pomalidomide Bortezomib Dexamethasone	18 Years -	Celgene
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma	NCT06163898	Multiple Myelom...	Alnuctamab Mezigdomide Dexamethasone	18 Years -	Celgene
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	NCT05981209	Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dexamethasone Echocardiograph... Elotuzumab Magnetic Resona... Mezigdomide X-Ray Imaging	18 Years -	Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	NCT06121843	Multiple Myelom...	BMS-986393 Alnuctamab Mezigdomide Iberdomide	18 Years -	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	NCT06121843	Multiple Myelom...	BMS-986393 Alnuctamab Mezigdomide Iberdomide	18 Years -	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Spots Global Cancer Trial Database for mezigdomide

Every month we try and update this database with for mezigdomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mezigdomide

Every month we try and update this database with for mezigdomide cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mezigdomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.